Nephros Introduces the “Nephros Challenge” Campaign

RIVER EDGE, N.J.--()--Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, announced today that it has launched the “Nephros Challenge” campaign, a program designed to encourage dialysis clinics to evaluate the performance improvement potential from using Nephros ultrafilters to assist in providing dialysis quality water or bicarbonate concentrate.

“We have confidence that our ultrafilters will improve the quality of water leading into the dialysis machines, and are willing to put a money-back guarantee on our dialysis ultrafiltration products.”

“Qualitative and quantitative feedback from our customers suggests that integrating our ultrafilters with a dialysis clinic’s water treatment system provides measurable improvements in the quality of its dialysis water,” said Daron Evans, President and CEO of Nephros. “We have confidence that our ultrafilters will improve the quality of water leading into the dialysis machines, and are willing to put a money-back guarantee on our dialysis ultrafiltration products.”

“The Nephros Challenge is simple. We encourage the dialysis clinics to develop their own evaluation metrics that include common variables associated with water quality. After six months of using Nephros ultrafilters, if a dialysis clinic does not see improvement in those metrics, then we will provide the clinics with a full refund of the cost of the ultrafilters.”

Nephros ultrafilters are used on the water and bicarbonate concentrate lines which feed into a hemodialysis machine. The ultrafilters retain particles as small as five nanometers (5nm), preventing bacteria, viruses and endotoxins from entering the machine. Nephros’ proprietary filter fiber provides superior protection and enables a five log reduction in levels of endotoxin, which is a key contributor to vascular inflammation in dialysis patients. In addition to providing superior levels of filtration, Nephros ultrafilters are FDA 510(k) cleared for a 12-month product life when used in dialysis clinics.

“Our goals are to increase awareness of the importance of water quality in dialysis and to encourage adoption of best practices to meet the recommendations of the ANSI/AAMI/ISO 11663:2009 standard. Many patients are not aware of the compendium of water quality standards and filtration performance, but their health can be affected by water quality in a profound way.”

For dialysis clinics that wish to enroll in the Nephros Challenge, or for patients who wish to know if their clinic has enrolled in the Nephros Challenge, they can contact Nephros at TheChallenge@Nephros.com.

About Nephros, Inc.

Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters, as well as a hemodiafiltration system for the treatment of patients with end stage kidney disease. Its filters, which it calls ultrafilters, are primarily used in dialysis centers for the removal of biological contaminants from water, bicarbonate concentrate and/or blood.

Nephros was founded in 1997 by healthcare professionals affiliated with Columbia University Medical Center/New York-Presbyterian Hospital to develop and commercialize a hemodiafiltration system, an alternative method to hemodialysis. Since its founding, the company has extended its filtration technologies to meet the demand for liquid purification in other areas, in particular water purification.

For more information about Nephros and its products, please visit the company’s website at www.nephros.com.

Forward-Looking Statements

This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Nephros Challenge, the ability of Nephros’ ultrafilters to improve the quality of water used in dialysis machines and patient outcomes, and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Nephros Inc.’s reports filed with the U.S. Securities and Exchange Commission, including with respect to Nephros, its Annual Report on Form 10-K for the year ended December 31, 2014. Nephros, Inc. does not undertake any responsibility to update the forward-looking statements in this release.

Contacts

Investors:
PCG Advisory Group
Kirin M. Smith, 646-863-6519
Chief Operating Officer
www.pcgadvisory.com

Nephros, Inc.